NHS England has today (29 April 2016) launched a 30 day public consultation on a proposed number of new products for specialised services, (including service specifications and clinical commissioning policies). There has already been extensive engagement on these national specifications and policies, as they have been developed with the support and input of lead clinicans and patient and public representatives. This approach has helped ensure that the views of key stakeholders have informed and influenced the development of the specifications and policies to date. Please note this is one of several public consultations on a proposed number of new draft products for specialised services. We now wish to test them further with wider groups of stakeholders.
Rituximab for the treatment of Primary Sjogren’s Syndrome (PSS) in adults (A13X03):
Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults) (A14X01):
Share
Share on Twitter Share on Facebook